OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
Christeen Samuel, Hannah Cornman, Anusha Kambala, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 3, pp. 729-749
Open Access | Times Cited: 108
Christeen Samuel, Hannah Cornman, Anusha Kambala, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 3, pp. 729-749
Open Access | Times Cited: 108
Showing 1-25 of 108 citing articles:
JAK-STAT pathway inhibitors in dermatology
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, et al.
Anais Brasileiros de Dermatologia (2023) Vol. 98, Iss. 5, pp. 656-677
Open Access | Times Cited: 44
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, et al.
Anais Brasileiros de Dermatologia (2023) Vol. 98, Iss. 5, pp. 656-677
Open Access | Times Cited: 44
Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin
Shawn G. Kwatra, Zachary A. Bordeaux, Varsha Parthasarathy, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 7, pp. 717-717
Open Access | Times Cited: 10
Shawn G. Kwatra, Zachary A. Bordeaux, Varsha Parthasarathy, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 7, pp. 717-717
Open Access | Times Cited: 10
Lichen Planus: What is New in Diagnosis and Treatment?
Burak Tekin, Fangyi Xie, Julia S. Lehman
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 5, pp. 735-764
Closed Access | Times Cited: 10
Burak Tekin, Fangyi Xie, Julia S. Lehman
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 5, pp. 735-764
Closed Access | Times Cited: 10
JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature
Seyed Mohammad Vahabi, Saeed Bahramian, Farzad Esmaeili, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 861-861
Open Access | Times Cited: 9
Seyed Mohammad Vahabi, Saeed Bahramian, Farzad Esmaeili, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 861-861
Open Access | Times Cited: 9
Topical anti-inflammatory treatments for eczema: network meta-analysis
S. Lax, Eleanor Van Vogt, Bridget Candy, et al.
Cochrane library (2024) Vol. 2024, Iss. 8
Closed Access | Times Cited: 8
S. Lax, Eleanor Van Vogt, Bridget Candy, et al.
Cochrane library (2024) Vol. 2024, Iss. 8
Closed Access | Times Cited: 8
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 91-91
Open Access | Times Cited: 1
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 91-91
Open Access | Times Cited: 1
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
Andrew Blauvelt, Richard Langley, Kenneth B. Gordon, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 12, pp. 3031-3042
Open Access | Times Cited: 17
Andrew Blauvelt, Richard Langley, Kenneth B. Gordon, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 12, pp. 3031-3042
Open Access | Times Cited: 17
Vitiligo: advances in pathophysiology research and treatment development
Zhussipbek Mukhatayev, I. Caroline Le Poole
Trends in Molecular Medicine (2024) Vol. 30, Iss. 9, pp. 844-862
Closed Access | Times Cited: 7
Zhussipbek Mukhatayev, I. Caroline Le Poole
Trends in Molecular Medicine (2024) Vol. 30, Iss. 9, pp. 844-862
Closed Access | Times Cited: 7
Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid‐resistant vitiligo: A prospective case series
Yijian Zhu, Zhengzhou Shi, Zhongyi Xu, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 7
Yijian Zhu, Zhengzhou Shi, Zhongyi Xu, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 7
Cendakimab in Patients With Moderate to Severe Atopic Dermatitis
Andrew Blauvelt, Emma Guttman‐Yassky, Charles Lynde, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 8, pp. 856-856
Open Access | Times Cited: 7
Andrew Blauvelt, Emma Guttman‐Yassky, Charles Lynde, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 8, pp. 856-856
Open Access | Times Cited: 7
Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
Li-Chi Chen, Chino Ogbutor, Kristen J. Kelley, et al.
Journal of the American Academy of Dermatology (2024) Vol. 90, Iss. 6, pp. 1260-1262
Closed Access | Times Cited: 6
Li-Chi Chen, Chino Ogbutor, Kristen J. Kelley, et al.
Journal of the American Academy of Dermatology (2024) Vol. 90, Iss. 6, pp. 1260-1262
Closed Access | Times Cited: 6
A prospective observational study of oral abrocitinib and narrow-band ultraviolet-B in refractory progressive vitiligo
Zhongyi Xu, Yijie Xuan, Yiyi Li, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 3, pp. 590-592
Closed Access | Times Cited: 5
Zhongyi Xu, Yijie Xuan, Yiyi Li, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 3, pp. 590-592
Closed Access | Times Cited: 5
Aggressive Cutaneous Squamous Cell Carcinoma in a Patient on Janus-Kinase Inhibitor Therapy
Ana M. Aragon Sierra, Kevin Donohoe, Daniel J. Canaday, et al.
JAAD Case Reports (2025) Vol. 57, pp. 67-70
Open Access
Ana M. Aragon Sierra, Kevin Donohoe, Daniel J. Canaday, et al.
JAAD Case Reports (2025) Vol. 57, pp. 67-70
Open Access
Refractory pityriasis rubra pilaris treated with abrocitinib
Filip Rob
Dermatology Reports (2025)
Open Access
Filip Rob
Dermatology Reports (2025)
Open Access
Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors
Victoria Fang, Radhika Gupta, Robert G. Micheletti
Dermatologic Clinics (2025) Vol. 43, Iss. 2, pp. 231-245
Closed Access
Victoria Fang, Radhika Gupta, Robert G. Micheletti
Dermatologic Clinics (2025) Vol. 43, Iss. 2, pp. 231-245
Closed Access
The future of topical JAK inhibitors in the treatment of atopic dermatitis
Joanna Mazgaj, Magdalena Kotewicz, Andrzej Jaworek, et al.
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Joanna Mazgaj, Magdalena Kotewicz, Andrzej Jaworek, et al.
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, et al.
Dermatology and Therapy (2025)
Open Access
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, et al.
Dermatology and Therapy (2025)
Open Access
Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions
Yan Zhang, Shaoying Yuan, Yixing Wu, et al.
Inflammopharmacology (2025)
Closed Access
Yan Zhang, Shaoying Yuan, Yixing Wu, et al.
Inflammopharmacology (2025)
Closed Access
A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)
Min Huang, Peng Li
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Min Huang, Peng Li
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
A practical approach to positioning therapies in ulcerative colitis
Russell Yanofsky, David T. Rubin
Journal of the Canadian Association of Gastroenterology (2025) Vol. 8, Iss. Supplement_2, pp. S6-S14
Open Access
Russell Yanofsky, David T. Rubin
Journal of the Canadian Association of Gastroenterology (2025) Vol. 8, Iss. Supplement_2, pp. S6-S14
Open Access
The small molecule ML233 is a direct inhibitor of tyrosinase function
Romain Menard, Aissette Baanannou, Caroline Halluin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Romain Menard, Aissette Baanannou, Caroline Halluin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Vitiligo: A Review of Pathogenesis and Treatments, Including New Therapies on the Horizon
Catalina Retamal Altbir, Dan Hartmann, Fernando Valenzuela
Journal of Cutaneous Medicine and Surgery (2025)
Closed Access
Catalina Retamal Altbir, Dan Hartmann, Fernando Valenzuela
Journal of Cutaneous Medicine and Surgery (2025)
Closed Access
Janus kinase inhibitors for the treatment of lichen Sclerosus: A systematic review
Chin‐Hsuan Shen, Shu-Hui Wang, Ching‐Chi Chi
British Journal of Clinical Pharmacology (2025)
Closed Access
Chin‐Hsuan Shen, Shu-Hui Wang, Ching‐Chi Chi
British Journal of Clinical Pharmacology (2025)
Closed Access
The small molecule ML233 is a direct inhibitor of tyrosinase function
Romain Menard, Aissette Baanannou, Caroline Halluin, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Romain Menard, Aissette Baanannou, Caroline Halluin, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
Marco Spadafora, Serena Morsia, Vito Di Lernia, et al.
Experimental Dermatology (2025) Vol. 34, Iss. 4
Open Access
Marco Spadafora, Serena Morsia, Vito Di Lernia, et al.
Experimental Dermatology (2025) Vol. 34, Iss. 4
Open Access
